Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more – Endpoints News
|
Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more
Endpoints News Pfizer and its partners at Astellas are anxious to get the FDA review underway for nonmetastatic prostate cancer, which could add considerably to its franchise value as generics start to slice and dice the market for J&J's rival therapy Zytiga. J&J has … |
